Magnesium hydroxide nanoparticles for treating arthralgia, and preparation method therefor and use thereof
By preparing magnesium hydroxide nanoparticles, using the "core-shell" structure of magnesium salt, hydroxide and phospholipids, the safety and poor results of the current joint pain treatment methods were solved, and long-term analgesic effects were achieved. Reduced the frequency of administration and significantly improved the quality of life of patients with osteoarthritis.
Patent Information
- Application Number
- PCT/CN2024/087375
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-05
- Filing Date
- 2024-04-12
- Publication Date
- 2024-11-14
AI Technical Summary
The existing joint pain treatment methods are not effective significantly in patients with osteoarthritis and have safety risks, especially long-term use of drugs such as nonsteroidal anti-inflammatory drugs and oral tramadol can cause cardiovascular and gastrointestinal side effects, and The analgesic effect lasts for a short time and cannot effectively delay the progress of the disease.
By preparing magnesium salts, hydroxides and phospholipids into magnesium hydroxide nanoparticles, nano-level drug preparation technology is used to form magnesium hydroxide nanoparticles with "core-shell" structure, which are used to treat joint pain and significantly prolong the zoster. Painful effect time and reduce the frequency of administration.
Magnesium hydroxide nanoparticles can effectively relieve joint pain, significantly prolong the analgesic time, reduce patient pain, and verify their safety and efficacy through rat experiments, providing a long-term and safe joint analgesic treatment plan.
Smart Images

Figure CN2024087375_14112024_PF_FP_ABST
Abstract
Description
Magnesium hydroxide nanoparticles for treating joint pain, preparation method and application thereof
[0001] This application claims priority to the Chinese patent application filed with the State Intellectual Property Office of China on May 5, 2023, with application number 202310496323.3 and invention patent name “Magnesium hydroxide nanoparticles for treating joint pain, preparation method and application thereof”, the entire contents of which are incorporated by reference into this application.
[0002] This application claims priority to the Chinese patent application filed with the State Intellectual Property Office of China on May 5, 2023, with application number 202310497579.6 and invention patent name “Application of magnesium hydroxide in the preparation of drugs for treating joint pain”, the entire contents of which are incorporated by reference into this application. Technical Field
[0003] The present invention belongs to the field of medicine, and in particular relates to magnesium hydroxide nanoparticles for treating joint pain, a preparation method thereof and an application thereof. Background Art
[0004] Osteoarthritis (OA) is a degenerative disease characterized by joint pain, often affecting the knees, hips, spine, and hands, resulting from fibrosis, cracking, ulceration, and loss of articular cartilage caused by multiple factors. Its pathological features include degeneration and destruction of articular cartilage, subchondral bone sclerosis or cystic changes, bone hyperplasia at the joint margins, and synovitis. OA severely impacts joint function and quality of life, and studies have shown that OA, particularly symptomatic knee OA, can significantly increase all-cause mortality. Unfortunately, there are currently no safe and effective treatments available to slow the progression of OA, both domestically and internationally.
[0005] Joint pain is the most common clinical manifestation of OA, and analgesia is the primary medical concern for OA patients. As the disease progresses, OA patients often experience persistent pain. Therefore, achieving long-term and safe analgesia is of great significance to OA patients.
[0006] Currently, the primary treatment for OA patients is joint analgesia. While there are numerous treatment options, they present numerous challenges. For example, acetaminophen has historically been a first-line treatment for OA pain, but recent high-quality research evidence suggests that it is ineffective compared to placebo in relieving OA pain and significantly increases the risk of gastrointestinal side effects. Oral nonsteroidal anti-inflammatory drugs (NSAIDs) are effective in relieving OA pain, but long-term use can cause cardiovascular and gastrointestinal side effects, raising concerns. Oral tramadol was recommended as a first-line treatment in both the 2013 American Academy of Orthopaedic Surgeons and the 2012 American College of Rheumatology OA guidelines. However, recent studies have found that oral tramadol significantly increases all-cause mortality, myocardial infarction, and hip fracture rates compared to NSAIDs (this has been incorporated into the 2019 American College of Rheumatology OA guidelines, which no longer recommend tramadol as a first-line treatment). Intra-articular corticosteroid injections are widely used and offer significant short-term analgesic effects, but they pose significant safety concerns, including a short-lived analgesic effect, inadequate efficacy, and safety risks. Therefore, there is an urgent need to further explore therapeutic drugs with significant efficacy and high safety for long-term analgesia of OA.
[0007] Therefore, based on this, the technical solution of the present invention is proposed.
[0008] Summary of the Invention
[0009] To address the problems of the prior art, the present invention provides magnesium hydroxide nanoparticles for treating joint pain and a method for preparing the same. The preparation method is simple and easy to control, and magnesium hydroxide nanoparticles can be prepared using only a magnesium salt, a hydroxide, and a phospholipid. Rat experiments have demonstrated that, after magnesium salt is prepared into nanoscale magnesium hydroxide using pharmaceutical formulation technology, the nanoparticles exhibit joint analgesia, with a significantly prolonged analgesic effect, significantly reducing the frequency of dosing and, in turn, alleviating patient pain.
[0010] The present invention provides magnesium hydroxide nanoparticles for treating joint pain. The magnesium hydroxide nanoparticles contain magnesium hydroxide and phospholipids.
[0011] Preferably, the magnesium hydroxide nanoparticles comprise a "core-shell" structure, wherein:
[0012] The core layer is magnesium hydroxide and the shell layer is phospholipid.
[0013] Preferably, the phospholipid is one of natural soybean lecithin, natural egg yolk lecithin or synthetic lecithin (such as hydrogenated lecithin).
[0014] Preferably, the phospholipid is one of phospholipids S45, S75, S100, SPC, E80, EPCS, EPG, SPC-3, PC98-T, PL-100M, HSPC, PGE, PGSH, DS-PL95E, DSPE, DPPA, DSPA or DMPC.
[0015] Preferably, the average particle size of the magnesium hydroxide nanoparticles is 50 to 550 nm.
[0016] Based on the same technical concept, the present invention further provides a method for preparing magnesium hydroxide nanoparticles for treating joint pain, the preparation method comprising the following steps:
[0017] (1) dissolving a soluble magnesium salt in purified water to obtain a magnesium salt solution;
[0018] (2) dissolving a soluble metal hydroxide in purified water to obtain a metal hydroxide solution;
[0019] (3) dissolving the phospholipid in an organic solvent to obtain a phospholipid solution;
[0020] (4) performing rotary evaporation on the phospholipid solution to remove the organic reagent, and after a thin film is formed, adding the magnesium salt solution to hydrate the solution to obtain a hydrated liquid;
[0021] (5) Adding the metal hydroxide solution to the hydration liquid to perform nano-processing, and after completion, obtaining the magnesium hydroxide nanoparticles for treating joint pain.
[0022] Preferably, in step (1), the soluble magnesium salt is a combination of one or more of anhydrous magnesium sulfate, magnesium sulfate monohydrate, magnesium sulfate heptahydrate, magnesium chloride, and magnesium chloride hexahydrate.
[0023] Preferably, in step (2), the metal hydroxide is sodium hydroxide or potassium hydroxide, or a combination of the two.
[0024] Preferably, in step (3), the organic solvent is volatile and can dissolve phospholipids, and is a combination of one or more of ethanol, dichloromethane or acetone.
[0025] Preferably, in step (5), the nano-processing method is one of probe ultrasonic processing, high-pressure homogenization processing or ball mill processing.
[0026] Based on the same technical concept, the present invention further provides an application of the magnesium hydroxide nanoparticles for treating joint pain, wherein the magnesium hydroxide nanoparticles are used to prepare a drug for treating joint pain caused by osteoarthritis.
[0027] The beneficial effects of the present invention are:
[0028] The preparation method of the present invention is simple and easy to control. Magnesium hydroxide nanoparticles can be prepared only by using magnesium salt, hydroxide and phospholipid. Rat experiments have verified that after magnesium salt is prepared into nano-scale magnesium hydroxide by means of pharmaceutical preparation technology, it has a joint analgesic effect and the analgesic effect lasts significantly longer, which will greatly reduce the frequency of administration and thus reduce the pain of patients. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the embodiments or the description of the prior art. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.
[0030] FIG1 is a TEM image of magnesium hydroxide nanoparticles in Experimental Example 1.
[0031] FIG2 is a graph showing the mechanical withdrawal threshold results of rats in each group in Experimental Example 2.
[0032] FIG3 is a data diagram showing the difference in bipedal weight bearing of rats in each group in Experimental Example 2. DETAILED DESCRIPTION
[0033] To make the objectives, technical solutions, and advantages of the present invention more apparent, the technical solutions of the present invention will be described in detail below. Obviously, the embodiments described are only some of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other implementations obtained by those of ordinary skill in the art without inventive effort are within the scope of protection of the present invention.
[0034] Example 1
[0035] This embodiment provides a method for preparing magnesium hydroxide nanoparticles for treating joint pain, the preparation method comprising the following steps:
[0036] (1) Dissolve 393.6 mg of magnesium sulfate heptahydrate in 4 mL of purified water to obtain a magnesium sulfate solution;
[0037] (2) Dissolve 8 mg of sodium hydroxide in 1 mL of purified water to obtain a sodium hydroxide solution;
[0038] (3) Dissolve 125 mg of egg yolk phospholipid E80 in 20 mL of dichloromethane to obtain a phospholipid solution;
[0039] (4) transferring the phospholipid solution to a round-bottom flask, removing the organic reagent by a rotary evaporator to form a thin film on the flask wall, and then hydrating the thin film with the magnesium sulfate solution to obtain a hydrated solution;
[0040] (5) The sodium hydroxide solution is quickly added to the hydration solution, and then ultrasonicated for 10 minutes using a 220W power probe. After completion, the magnesium hydroxide nanoparticles for treating joint pain are obtained. The average particle size thereof is determined to be 338.5 nm by a laser particle size analyzer.
[0041] Example 2
[0042] This embodiment provides a method for preparing magnesium hydroxide nanoparticles for treating joint pain, the preparation method comprising the following steps:
[0043] (1) Dissolve 393.6 mg of magnesium sulfate heptahydrate in 4 mL of purified water to obtain a magnesium sulfate solution;
[0044] (2) Dissolve 12 mg of sodium hydroxide in 1 mL of purified water to obtain a sodium hydroxide solution;
[0045] (3) Dissolve 125 mg of egg yolk phospholipid E80 in 30 mL of dichloromethane to obtain a phospholipid solution;
[0046] (4) transferring the phospholipid solution to a round-bottom flask, removing the organic reagent by a rotary evaporator to form a thin film on the flask wall, and then hydrating the thin film with the magnesium sulfate solution to obtain a hydrated solution;
[0047] (5) The sodium hydroxide solution is quickly added to the hydration solution, and then ultrasonicated for 10 minutes using a 220W power probe. After completion, the magnesium hydroxide nanoparticles for treating joint pain are obtained. The average particle size thereof is determined to be 445.0 nm by a laser particle size analyzer.
[0048] Example 3
[0049] This embodiment provides a method for preparing magnesium hydroxide nanoparticles for treating joint pain, the preparation method comprising the following steps:
[0050] (1) Dissolve 393.6 mg of magnesium sulfate heptahydrate in 4 mL of purified water to obtain a magnesium sulfate solution;
[0051] (2) Dissolve 16 mg of sodium hydroxide in 1 mL of purified water to obtain a sodium hydroxide solution;
[0052] (3) Dissolve 125 mg of egg yolk phospholipid E80 in 20 mL of dichloromethane to obtain a phospholipid solution;
[0053] (4) transferring the phospholipid solution to a round-bottom flask, removing the organic reagent by a rotary evaporator to form a thin film on the flask wall, and then hydrating the thin film with the magnesium sulfate solution to obtain a hydrated solution;
[0054] (5) The sodium hydroxide solution is quickly added to the hydration solution, and then ultrasonicated for 10 minutes using a 220W power probe. After completion, the magnesium hydroxide nanoparticles for treating joint pain are obtained. The average particle size thereof is measured by a laser particle size analyzer to be 539.5 nm.
[0055] Example 4
[0056] This embodiment provides a method for preparing magnesium hydroxide nanoparticles for treating joint pain, the preparation method comprising the following steps:
[0057] (1) Dissolve 393.6 mg of magnesium sulfate heptahydrate in 4 mL of purified water to obtain a magnesium sulfate solution;
[0058] (2) Dissolve 32 mg of sodium hydroxide in 1 mL of purified water to obtain a sodium hydroxide solution;
[0059] (3) Dissolve 125 mg of egg yolk phospholipid E80 in 20 mL of dichloromethane to obtain a phospholipid solution;
[0060] (4) transferring the phospholipid solution to a round-bottom flask, removing the organic reagent by a rotary evaporator to form a thin film on the flask wall, and then hydrating the thin film with the magnesium sulfate solution to obtain a hydrated solution;
[0061] (5) The sodium hydroxide solution is quickly added to the hydration liquid, and then treated with a high-pressure homogenizer at 6000 psi for 5 minutes. After completion, the magnesium hydroxide nanoparticles for treating joint pain are obtained. The average particle size thereof is measured by a laser particle size analyzer to be 398.5 nm.
[0062] Example 5
[0063] This embodiment provides a method for preparing magnesium hydroxide nanoparticles for treating joint pain, the preparation method comprising the following steps:
[0064] (1) Dissolve 192 mg of anhydrous magnesium sulfate in 4 mL of purified water to obtain a magnesium sulfate solution;
[0065] (2) Dissolve 8 mg of sodium hydroxide in 1 mL of purified water to obtain a sodium hydroxide solution;
[0066] (3) Dissolve 125 mg of egg yolk phospholipid E80 in 20 mL of dichloromethane to obtain a phospholipid solution;
[0067] (4) transferring the phospholipid solution to a round-bottom flask, removing the organic reagent by a rotary evaporator to form a thin film on the flask wall, and then hydrating the thin film with the magnesium sulfate solution to obtain a hydrated solution;
[0068] (5) The sodium hydroxide solution is quickly added to the hydration solution, and then ultrasonicated for 10 minutes using a 220W power probe. After completion, the magnesium hydroxide nanoparticles for treating joint pain are obtained. The average particle size thereof is measured by a laser particle size analyzer to be 313.6 nm.
[0069] Example 6
[0070] This embodiment provides a method for preparing magnesium hydroxide nanoparticles for treating joint pain, the preparation method comprising the following steps:
[0071] (1) Dissolve 1.2 g of magnesium sulfate heptahydrate in 12 mL of purified water to obtain a magnesium sulfate solution;
[0072] (2) Dissolve 48 mg of sodium hydroxide in 3 mL of purified water to obtain a sodium hydroxide solution;
[0073] (3) Dissolve 350 mg of soybean lecithin S100 in 60 mL of dichloromethane to obtain a lecithin solution;
[0074] (4) transferring the phospholipid solution to a round-bottom flask, removing the organic reagent by a rotary evaporator to form a thin film on the flask wall, and then hydrating the thin film with the magnesium sulfate solution to obtain a hydrated solution;
[0075] (5) The sodium hydroxide solution is quickly added to the hydration liquid, and then treated with a high-pressure homogenizer at 6000 psi for 5 minutes. After completion, the magnesium hydroxide nanoparticles for treating joint pain are obtained. The average particle size thereof is measured by a laser particle size analyzer to be 363.9 nm.
[0076] Example 7
[0077] This embodiment provides a method for preparing magnesium hydroxide nanoparticles for treating joint pain, the preparation method comprising the following steps:
[0078] (1) Dissolve 393.6 mg of magnesium sulfate heptahydrate in 4 mL of purified water to obtain a magnesium sulfate solution;
[0079] (2) Dissolve 8 mg of sodium hydroxide in 1 mL of purified water to obtain a sodium hydroxide solution;
[0080] (3) Dissolve 60 mg of egg yolk phospholipid E80 in 20 mL of dichloromethane to obtain a phospholipid solution;
[0081] (4) transferring the phospholipid solution to a round-bottom flask, removing the organic reagent by a rotary evaporator to form a thin film on the flask wall, and then hydrating the thin film with the magnesium sulfate solution to obtain a hydrated solution;
[0082] (5) The sodium hydroxide solution is quickly added to the hydration solution, and then ultrasonicated for 10 minutes using a 220W power probe. After completion, the magnesium hydroxide nanoparticles for treating joint pain are obtained. The average particle size thereof is determined to be 411.7 nm by a laser particle size analyzer.
[0083] Example 8
[0084] This embodiment provides a method for preparing magnesium hydroxide nanoparticles for treating joint pain, the preparation method comprising the following steps:
[0085] (1) Dissolve 440 mg of magnesium sulfate monohydrate in 8 mL of purified water to obtain a magnesium sulfate solution;
[0086] (2) Dissolve 16 mg of sodium hydroxide in 2 mL of purified water to obtain a sodium hydroxide solution;
[0087] (3) Dissolve 200 mg of egg yolk lecithin PC98-T in 50 mL of anhydrous ethanol to obtain a phospholipid solution;
[0088] (4) transferring the phospholipid solution to a round-bottom flask, removing the organic reagent by a rotary evaporator to form a thin film on the flask wall, and then hydrating the thin film with the magnesium sulfate solution to obtain a hydrated solution;
[0089] (5) The sodium hydroxide solution was quickly added to the hydration solution, and then the solution was processed by a ball mill (Emax ball mill, Retsch, Germany) at 800 rpm for 2 h. After the process, the magnesium hydroxide nanoparticles for treating joint pain were obtained. The average particle size of the magnesium hydroxide nanoparticles was 206.5 nm as measured by a laser particle size analyzer.
[0090] Example 9
[0091] This embodiment provides a method for preparing magnesium hydroxide nanoparticles for treating joint pain, the preparation method comprising the following steps:
[0092] (1) Dissolve 200 mg of anhydrous magnesium chloride (Aladdin, purity 99%) in 8 mL of purified water to obtain a magnesium chloride solution;
[0093] (2) Dissolve 16 mg of sodium hydroxide in 2 mL of purified water to obtain a sodium hydroxide solution;
[0094] (3) Dissolve 200 mg of egg yolk lecithin PC98-T in 50 mL of anhydrous ethanol to obtain a phospholipid solution;
[0095] (4) transferring the phospholipid solution to a round-bottom flask, removing the organic reagent by a rotary evaporator to form a thin film on the flask wall, and then hydrating the thin film with the magnesium chloride solution to obtain a hydrated liquid;
[0096] (5) The sodium hydroxide solution was quickly added to the hydration solution, and then the solution was processed by a ball mill (Emax ball mill, Retsch, Germany) at 800 rpm for 2 h. After the process, the magnesium hydroxide nanoparticles for treating joint pain were obtained. The average particle size thereof was determined to be 228.1 nm by a laser particle size analyzer.
[0097] Example 10
[0098] This embodiment provides a method for preparing magnesium hydroxide nanoparticles for treating joint pain, the preparation method comprising the following steps:
[0099] (1) Dissolve 420 mg of magnesium chloride hexahydrate (Aladdin, purity 99%) in 8 mL of purified water to obtain a magnesium chloride solution;
[0100] (2) Dissolve 16 mg of sodium hydroxide in 2 mL of purified water to obtain a sodium hydroxide solution;
[0101] (3) Dissolve 200 mg of egg yolk lecithin PC98-T in 50 mL of anhydrous ethanol to obtain a phospholipid solution;
[0102] (4) transferring the phospholipid solution to a round-bottom flask, removing the organic reagent by a rotary evaporator to form a thin film on the flask wall, and then hydrating the thin film with the magnesium chloride solution to obtain a hydrated liquid;
[0103] (5) The sodium hydroxide solution was quickly added to the hydration solution, and then the solution was processed by a ball mill (Emax ball mill, Retsch, Germany) at 800 rpm for 2 h. After completion, the magnesium hydroxide nanoparticles for treating joint pain were obtained. The average particle size thereof was determined to be 235.0 nm by a laser particle size analyzer.
[0104] Example 11
[0105] This embodiment provides a method for preparing magnesium hydroxide nanoparticles for treating joint pain, the preparation method comprising the following steps:
[0106] (1) Dissolve 440 mg of magnesium sulfate monohydrate in 8 mL of purified water to obtain a magnesium sulfate solution;
[0107] (2) Dissolve 16 mg of sodium hydroxide in 2 mL of purified water to obtain a sodium hydroxide solution;
[0108] (3) Dissolve 800 mg of egg yolk lecithin PC98-T in 50 mL of anhydrous ethanol to obtain a phospholipid solution;
[0109] (4) transferring the phospholipid solution to a round-bottom flask, removing the organic reagent by a rotary evaporator to form a thin film on the flask wall, and then hydrating the thin film with the magnesium sulfate solution to obtain a hydrated solution;
[0110] (5) The sodium hydroxide solution was quickly added to the hydration solution, and then the solution was processed by a ball mill (Emax ball mill of Retsch, Germany) at 1000 rpm for 6 h. After the process, the magnesium hydroxide nanoparticles for treating joint pain were obtained. The average particle size thereof was determined to be 65.3 nm by a laser particle size analyzer.
[0111] Comparative Example 1
[0112] 125 mg of egg yolk phospholipid E80 was dissolved in 20 mL of dichloromethane and transferred to a round-bottom flask. The organic reagent was removed by rotary evaporation to form a thin film on the flask wall. The thin film was hydrated with 5 mL of purified water to form a hydrated liquid. The film was then ultrasonicated with a power probe of 220 W for 10 minutes to obtain blank liposomes.
[0113] Comparative Example 2
[0114] (1) Dissolve 393.6 mg of magnesium sulfate heptahydrate in 4 mL of purified water to obtain a magnesium sulfate solution;
[0115] (2) Dissolve 8 mg of sodium hydroxide in 1 mL of purified water to obtain a sodium hydroxide solution;
[0116] (3) The sodium hydroxide solution was quickly added to the magnesium sulfate solution, and then ultrasonicated for 10 minutes using a 220W power probe. The results showed that the system presented a clear white precipitate, and the particle size was beyond the measurement range of the laser particle size analyzer.
[0117] Test Example 1
[0118] The internal structure of the magnesium hydroxide nanoparticles of the present invention was observed.
[0119] The structure of the magnesium hydroxide nanoparticles prepared in Example 1 was observed by transmission electron microscopy (TEM). The result is shown in FIG1 . The magnesium hydroxide nanoparticles prepared in the present invention are spherical in shape and can be coated with phospholipids.
[0120] Test Example 2
[0121] The effect of the magnesium hydroxide nanoparticles of the present invention was tested.
[0122] (1) OA rat model
[0123] Sodium iodoacetate was injected into the articular cavity of the knee joint of SD rats to construct an OA rat model. When the rat knee joint swelled and the pain threshold was significantly reduced, the OA rat model was obtained.
[0124] (2) Pharmacodynamic studies
[0125] OA model rats were treated by intra-articular injection with normal saline (denoted as the normal saline group), blank liposomes prepared in Comparative Example 1 (denoted as the blank liposome group), magnesium sulfate solution (magnesium sulfate heptahydrate was dissolved in normal saline, denoted as the magnesium sulfate solution group), magnesium hydroxide nanoparticle solution prepared in Example 1 (denoted as magnesium hydroxide nanoparticle group 1), magnesium hydroxide nanoparticle solution prepared in Example 3 (denoted as magnesium hydroxide nanoparticle group 2), and magnesium hydroxide nanoparticle solution prepared in Example 11 (denoted as magnesium hydroxide nanoparticle group 3).
[0126] In addition, an equal volume (100 μL) of normal saline was injected into the knee joint cavity of normal rats as a control (referred to as the normal group). Each group received a 0.4 mmol / mL (calculated as magnesium) dose on the seventh day after modeling, for a total of one administration. Starting from the first day of administration, the mechanical withdrawal threshold and bipedal weight bearing difference of each group were measured weekly. The results are shown in Figures 2 and 3, respectively.
[0127] As shown in Figures 2 and 3, the magnesium hydroxide nanoparticles prepared by the present invention can effectively and durably relieve the joint pain of OA rats. At the same time, these results fully demonstrate that the magnesium hydroxide nanoparticles of the present invention can be used to prepare drugs for treating joint analgesia.
[0128] The above description is merely a specific embodiment of the present invention, but the scope of protection of the present invention is not limited thereto. Any modifications or substitutions that can be easily conceived by a person skilled in the art within the technical scope disclosed in the present invention should be included within the scope of protection of the present invention. Therefore, the scope of protection of the present invention should be based on the scope of protection of the claims.
Claims
1. A magnesium hydroxide nanoparticle for treating joint pain, characterized in that: The magnesium hydroxide nanoparticles contain magnesium hydroxide and phospholipids.
2. The magnesium hydroxide nanoparticles for treating joint pain according to claim 1, characterized in that: The magnesium hydroxide nanoparticles comprise a "core-shell" structure, wherein: The core layer is magnesium hydroxide and the shell layer is phospholipid.
3. The magnesium hydroxide nanoparticles for treating joint pain according to claim 1, characterized in that: The phospholipids are one or more of natural soybean phospholipids, natural egg yolk phospholipids or synthetic phospholipids.
4. The magnesium hydroxide nanoparticles for treating joint pain according to claim 3, characterized in that: The phospholipid is a combination of one or more of phospholipids S45, S75, S100, SPC, E80, EPCS, EPG, SPC-3, PC98-T, PL-100M, HSPC, PGE, PGSH, DS-PL95E, DSPE, DPPA, DSPA or DMPC.
5. The magnesium hydroxide nanoparticles for treating joint pain according to claim 4, characterized in that: The average particle size of the magnesium hydroxide nanoparticles is 50 to 550 nm.
6. The method for preparing magnesium hydroxide nanoparticles for treating joint pain according to any one of claims 1 to 5, characterized in that: The preparation method comprises the following steps: (1) dissolving a soluble magnesium salt in purified water to obtain a magnesium salt solution; (2) dissolving a soluble metal hydroxide in purified water to obtain a metal hydroxide solution; (3) dissolving the phospholipid in an organic solvent to obtain a phospholipid solution; (4) performing rotary evaporation on the phospholipid solution to remove the organic reagent, and after a thin film is formed, adding the magnesium salt solution to hydrate the solution to obtain a hydrated solution; (5) Adding the metal hydroxide solution to the hydration liquid for nano-processing, and obtaining the magnesium hydroxide nanoparticles for treating joint pain.
7. The method for preparing magnesium hydroxide nanoparticles for treating joint pain according to claim 6, characterized in that in step (1), the soluble magnesium salt is a combination of one or more of anhydrous magnesium sulfate, magnesium sulfate monohydrate, magnesium sulfate heptahydrate, magnesium chloride, and magnesium chloride hexahydrate.
8. The method for preparing magnesium hydroxide nanoparticles for treating joint pain according to claim 6, characterized in that: In step (2), the metal hydroxide is one or a combination of sodium hydroxide or potassium hydroxide.
9. The method for preparing magnesium hydroxide nanoparticles for treating joint pain according to claim 6, characterized in that: In step (5), the nano-processing method is one of probe ultrasonic processing, high-pressure homogenization processing or ball mill processing.
10. The use of magnesium hydroxide nanoparticles for treating joint pain according to any one of claims 1 to 5, characterized in that: The magnesium hydroxide nanoparticles are used for preparing medicine for treating joint pain caused by osteoarthritis.
Citation Information
Patent Citations
Application of magnesium hydroxide in preparing medicine for treating joint pain
CN117562920B
Formulations and methods for delaying onset of chronic neuropathic pain
CN104427987A
Orally-taken meal supplementing medicament for treating osteoarthritis
CN108719998A
Magnesium hydroxide nanoparticles for treating arthralgia as well as preparation method and application of magnesium hydroxide nanoparticles
CN117562869A
Magnesium fortified food product and additive
EP1792543A1
